Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Anti-HER-2×anti-CD3 Bi-specific Antibodies Inhibit Growth of HCT-116 Colorectal Carcinoma Cells in Vitro and in Vivo

  • Ren, Hui (Department of General Surgery, the Second Hospital, Jilin University) ;
  • Li, Jun (Department of Hematology and Oncology, China-Japan Union Hospital of Jilin University) ;
  • Liu, Jing-Jing (Department of General Surgery, the Second Hospital, Jilin University) ;
  • Guo, Hui-Ling (Department of General Surgery, the Second Hospital, Jilin University) ;
  • Jiang, Tao (Department of General Surgery, China-Japan Union Hospital of Jilin University)
  • Published : 2012.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: This study is conducted to evaluate the effects of anti-HER-2${\times}$anti-CD3 bi-specific antibodies(BsAb) on HER-2/neuover-expressing human colorectal carcinoma cells. Methods: Growth was assessed by MTT assays after exposure of HCT-116 cells to Herceptin, anti-CD3 and BsAb antibodies. Immunocytochemistry was applied to test the HER-2 level of HCT-116. In a nude mouse model, HER-2${\times}$CD3 BsAb was combined with effector cells (peripheral blood lymph cells from normal human being) for observations on in Vivo growth of tumors. Results: Compared with the control group, using effector cells combined with anti-CD3 McAb, Herceptin or HER2${\times}$CD3 BsAb, tumor cell growth in vitro and in vivo was significantly inhibited (P<0.05), most remarkably in the HER2${\times}$CD3 BsAb case. The growth of xenografts with HER2${\times}$CD3 BsAb combined with effector cells was also significantly inhibited when compared with the anti-CD3 McAb or Herceptin groups (P<0.05). Conclusion: HER-2/neu might be a useful target for immunotherapy in colorectal carcinoma, anti-HER2${\times}$anti-CD3 BsAb exerting clear anti-tumor effects.

Keywords

References

  1. Albarello L, Pecciarini L, Doglioni C (2011). HER2 testing in gastric cancer. Adv Anat Pathol, 18, 53-9. https://doi.org/10.1097/PAP.0b013e3182026d72
  2. Argyriou AA, Kalofonos HP (2009). Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors. Mol Med, 15, 183-91. https://doi.org/10.1007/s00894-008-0416-7
  3. Bang YJ, Van Cutsem E, Feyereislova A, et al (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376, 687-97. https://doi.org/10.1016/S0140-6736(10)61121-X
  4. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1999). Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res, 58, 2825-31.
  5. Chatenoud L (1993). CD3 antibody treatment stimulates the functional capability of regulatory T cells. Novartis Found Symp, 252:279-86; discussion 286-90.
  6. Cuello M, Ettenberg SA, Clark AS, et al (2001). Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligandmediated apoptosis in breast and ovarian cancer cell lines that over-express erbB- 2. Cancer Res, 61, 4892-900.
  7. Huang L, Chen S, Zha X, et al (2012). Expression feature of CD3, $Fc{\varepsilon}RI{\gamma}$, and Zap-70 in patients with chronic lymphocytic leukemia. Hematology, 17, 71-5. https://doi.org/10.1179/102453312X13221316477895
  8. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
  9. Kiewe P, Hasmüller S, Kahlert S, et al (2006). Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res, 12, 3085-91. https://doi.org/10.1158/1078-0432.CCR-05-2436
  10. Liu HQ, Zhang SL, Song S (2012). HER-2/neu and TOPIIa expression in gastric cancer reflect disease severity. Hepatogastroenterology, 59, 1290-3.
  11. Morishita A, Gong J, Nomura T, et al (2010). The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer. Int J Oncol, 37, 829-35.
  12. Nishio J, Feuerer M, Wong J, Mathis D, Benoist C (2010). Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints. J Exp Med, 207, 1879-89. https://doi.org/10.1084/jem.20100205
  13. Schroeder P, Lindemann C, Dettmar K, et al (2011). Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment. Clin Transl Oncol, 13, 889-98. https://doi.org/10.1007/s12094-011-0751-5
  14. Somlo G, Martel CL, Lau SK, et al (2012). A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer. Breast Cancer Res Treat, 131, 899-906. Epub 2011 Nov 1. https://doi.org/10.1007/s10549-011-1850-2
  15. Xia L, Yuan YZ, Xu CD, et al (2002). Effects of epidermal growth factor on the growth of human colorectal cancer cell and the implanted tumor of nude mice. World J Gastroenterol, 8, 455-8.

Cited by

  1. MicroRNA-451 Inhibits Growth of Human Colorectal Carcinoma Cells via Downregulation of Pi3k/Akt Pathway vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3631
  2. Lack of Effects of HER-2/neu on Prognosis in Colorectal Cancer: a Meta-analysis vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5551